Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NCNA 
NuCana PLC (NCNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NCNA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $104
1 Year Target Price $104
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.7% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.18M USD | Price to earnings Ratio - | 1Y Target Price 104 |
Price to earnings Ratio - | 1Y Target Price 104 | ||
Volume (30-day avg) 1 | Beta 1.42 | 52 Weeks Range 3.05 - 1650.00 | Updated Date 08/29/2025 |
52 Weeks Range 3.05 - 1650.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1727.21 |
Earnings Date
Report Date 2025-08-21 | When - | Estimate - | Actual -31.1302 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -71.53% | Return on Equity (TTM) -567.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5086622 | Price to Sales(TTM) - |
Enterprise Value -5086622 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.3 | Shares Outstanding 1908080 | Shares Floating 9539268049 |
Shares Outstanding 1908080 | Shares Floating 9539268049 | ||
Percent Insiders - | Percent Institutions 0.24 |
Upturn AI SWOT
NuCana PLC
Company Overview
History and Background
NuCana PLC is a biopharmaceutical company focused on developing precision medicines that transform treatment strategies for patients with cancer. It was founded in 2008. A significant milestone was the development of ProTide technology. Over time, it shifted its focus to oncology.
Core Business Areas
- Oncology Drug Development: NuCana develops novel oncology medicines, primarily using its ProTide technology to improve the effectiveness and safety of existing chemotherapy agents.
Leadership and Structure
Hugh Griffith serves as the Chief Executive Officer. The company operates with a board of directors overseeing strategic decisions and an executive team managing day-to-day operations.
Top Products and Market Share
Key Offerings
- Acelarin: Acelarin is a ProTide transformation of gemcitabine. It is being developed for various solid tumors. Currently, it does not have substantial market share pending regulatory approval. Competitors include generic gemcitabine and other chemotherapy agents.
- NUC-3373: NUC-3373 is a ProTide transformation of 5-fluorouracil (5-FU). It is being developed for advanced colorectal cancer and other solid tumors. Currently, it does not have substantial market share pending regulatory approval. Competitors include 5-FU and other chemotherapy agents for these cancers.
Market Dynamics
Industry Overview
The oncology drug market is large and growing, driven by an aging population and advancements in cancer research. It is highly competitive, with numerous established pharmaceutical companies and emerging biotech firms.
Positioning
NuCana positions itself as an innovator in cancer therapy through its ProTide technology, which aims to overcome resistance mechanisms and improve the therapeutic index of existing drugs. Its competitive advantage lies in this novel approach.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is estimated to be hundreds of billions of dollars. NuCana is positioned to capture a segment of this market with successful development and commercialization of its ProTide products.
Upturn SWOT Analysis
Strengths
- Proprietary ProTide technology platform
- Potential to improve the efficacy and safety of existing chemotherapies
- Experienced management team
- Focus on unmet medical needs in oncology
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- No currently marketed products
- High risk associated with drug development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new oncology indications
- Positive clinical trial results
- Regulatory approvals for its pipeline products
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- GILD
- MRK
- BMY
Competitive Landscape
NuCana faces competition from larger pharmaceutical companies with greater resources and established market presence. Its advantage lies in its novel ProTide technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress and clinical trial advancements rather than revenue generation.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals for its pipeline products. Analyst estimates are subject to variability.
Recent Initiatives: Recent initiatives include advancing clinical trials for Acelarin and NUC-3373 and exploring potential partnerships.
Summary
NuCana is a high-risk, high-reward biopharmaceutical company with promising technology but no currently marketed products. Its success hinges on positive clinical trial outcomes and securing regulatory approvals. It faces strong competition and financial constraints. The company needs to navigate regulatory hurdles and secure partnerships to achieve its potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Third-party financial data providers (unavailable without real-time access)
- Industry reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information provided is subject to change without notice. Market share data is approximate and based on general industry knowledge. All financial data is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NuCana PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-09-28 | Founder, CEO & Executive Director Mr. Hugh Stephen Griffith | ||
Sector Healthcare | Industry Biotechnology | Full time employees 20 | Website https://www.nucana.com |
Full time employees 20 | Website https://www.nucana.com | ||
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1 modular clinical trial for patients with advanced solid tumors and lung cancer. The company is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.